Disclosed in the present invention is a new application for a long-acting mutant human fibroblast growth factor, the long-acting mutant human fibroblast growth factor being PEGylation Recombinant Human-mouse Chimeric Fibroblast Growth Factor 21, and the new application being the preparation of a drug for the treatment of non-alcoholic steatohepatitis.